Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

BACKGROUND: Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator. CASE PRESENTATIONS: We report a series of four patients, diagnosed w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Song, Johanna S., Tawa, Marianne, Chau, Nicole G., Kupper, Thomas S., LeBoeuf, Nicole R.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356405/
https://ncbi.nlm.nih.gov/pubmed/28302100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3194-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares